Anita Riecher-rössler

List of Publications by Year
in descending order

250 papers	15,895 citations	29928 54 h-index	20222 117 g-index
297 all docs	297 docs citations	297 times ranked	15885 citing authors

#	Article	IF	Citations
1	The Psychosis High-Risk State. JAMA Psychiatry, 2013, 70, 107.	11.4	1,256
2	Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nature Medicine, 1998, 4, 713-717.	30.1	1,057
3	Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet, The, 2008, 371, 1085-1097.	12.1	980
4	Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. Biological Psychiatry, 2018, 84, 644-654.	1.3	699
5	The Influence of Age and Sex on the Onset and Early Course of Schizophrenia. British Journal of Psychiatry, 1993, 162, 80-86.	3.6	601
6	Size of burden of schizophrenia and psychotic disorders. European Neuropsychopharmacology, 2005, 15, 399-409.	1.6	524
7	Accelerated Brain Aging in Schizophrenia and Beyond: A Neuroanatomical Marker of Psychiatric Disorders. Schizophrenia Bulletin, 2014, 40, 1140-1153.	4.6	389
8	Heterogeneity of Psychosis Risk Within Individuals at Clinical High Risk. JAMA Psychiatry, 2016, 73, 113.	11.4	367
9	Sex and gender differences in mental disorders. Lancet Psychiatry,the, 2017, 4, 8-9.	7.6	366
10	Regional Gray Matter Volume Abnormalities in the At Risk Mental State. Biological Psychiatry, 2007, 61, 1148-1156.	1.3	298
11	Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST). American Journal of Psychiatry, 2009, 166, 675-682.	8.7	293
12	Prediction Models of Functional Outcomes for Individuals in the Clinical High-Risk State for Psychosis or With Recent-Onset Depression. JAMA Psychiatry, 2018, 75, 1156.	11.4	268
13	Psychotic experiences in the general population: A twenty-year prospective community study. Schizophrenia Research, 2007, 92, 1-14.	2.1	267
14	Intervention in Individuals at Ultra-High Risk for Psychosis. Journal of Clinical Psychiatry, 2009, 70, 1206-1212.	2.3	261
15	Efficacy of Using Cognitive Status in Predicting Psychosis: A 7-Year Follow-Up. Biological Psychiatry, 2009, 66, 1023-1030.	1.3	245
16	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. Schizophrenia Bulletin, 2014, 40, 729-736.	4.6	235
17	Neuroanatomical Abnormalities That Predate the Onset of Psychosis. Archives of General Psychiatry, 2011, 68, 489.	13.2	230
18	Effect of Ï‰-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders. JAMA Psychiatry, 2017, 74, 19.	11.4	223

#	Article	IF	Citations
19	At risk or not at risk? A metaâ€analysis of the prognostic accuracy of psychometric interviews for psychosis prediction. World Psychiatry, 2015, 14, 322-332.	9.6	212
20	Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. Schizophrenia Research, 2008, 106, 108-114.	2.1	211
21	A Randomized, Double-Blind, Placebo-Controlled Study of Light Therapy for Antepartum Depression. Journal of Clinical Psychiatry, 2011, 72, 986-993.	2.3	200
22	The Dark Side of the Moon: Meta-analytical Impact of Recruitment Strategies on Risk Enrichment in the Clinical High Risk State for Psychosis. Schizophrenia Bulletin, 2016, 42, 732-743.	4.6	186
23	First onset and early symptomatology of schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 1992, 242, 109-118.	3.4	182
24	Sex and gender differences in schizophrenic psychosesâ€"a critical review. Archives of Women's Mental Health, 2018, 21, 627-648.	2.8	151
25	Multimodal Machine Learning Workflows for Prediction of Psychosis in Patients With Clinical High-Risk Syndromes and Recent-Onset Depression. JAMA Psychiatry, 2021, 78, 195.	11.4	146
26	Schizophrenia and oestrogens â€" is there an association?. European Archives of Psychiatry and Clinical Neuroscience, 1993, 242, 323-328.	3.4	144
27	Detecting the Psychosis Prodrome Across High-Risk Populations Using Neuroanatomical Biomarkers. Schizophrenia Bulletin, 2015, 41, 471-482.	4.6	144
28	Disease Prediction in the At-Risk Mental State for Psychosis Using Neuroanatomical Biomarkers: Results From the FePsy Study. Schizophrenia Bulletin, 2012, 38, 1234-1246.	4.6	142
29	Individualized differential diagnosis of schizophrenia and mood disorders using neuroanatomical biomarkers. Brain, 2015, 138, 2059-2073.	8.0	135
30	Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis. British Journal of Psychiatry, 2007, 191, s69-s75.	3.6	131
31	Oestrogens, prolactin, hypothalamic-pituitary-gonadal axis, and schizophrenic psychoses. Lancet Psychiatry,the, 2017, 4, 63-72.	7.6	119
32	Moving beyond transition outcomes: Meta-analysis of remission rates in individuals at high clinical risk for psychosis. Psychiatry Research, 2013, 209, 266-272.	3.4	115
33	Acute Effects of Heroin on Negative Emotional Processing: Relation of Amygdala Activity and Stress-Related Responses. Biological Psychiatry, 2014, 76, 289-296.	1.3	113
34	Further evidence for a specific role of estradiol in schizophrenia?. Biological Psychiatry, 1994, 36, 492-494.	1.3	97
35	Influence of the menstrual cycle phase on the therapeutic response in schizophrenia. Biological Psychiatry, 1994, 36, 137-139.	1.3	97
36	Brain Connectivity Abnormalities Predating the Onset of Psychosis. JAMA Psychiatry, 2013, 70, 903.	11.4	94

#	ARTICLE	IF	CITATIONS
37	Neuropsychological deficits in individuals with an at risk mental state for psychosis â€" Working memory as a potential trait marker. Schizophrenia Research, 2007, 97, 14-24.	2.1	88
38	Whither the Attenuated Psychosis Syndrome?. Schizophrenia Bulletin, 2012, 38, 1130-1134.	4.6	85
39	Hippocampus abnormalities in at risk mental states for psychosis? A cross-sectional high resolution region of interest magnetic resonance imaging study. Journal of Psychiatric Research, 2010, 44, 447-453.	3.2	82
40	Hyperprolactinaemia in early psychosisâ€"not only due to antipsychotics. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1342-1344.	5.0	75
41	Short-term metreleptin treatment of patients with anorexia nervosa: rapid on-set of beneficial cognitive, emotional, and behavioral effects. Translational Psychiatry, 2020, 10, 303.	4.9	75
42	Clinical and functional long-term outcome of patients at clinical high risk (CHR) for psychosis without transition to psychosis: A systematic review. Schizophrenia Research, 2019, 210, 39-47.	2.1	70
43	Domestic violence against women: Definitions, epidemiology, risk factors and consequences. Swiss Medical Weekly, 2010, 140, w13099.	1.5	70
44	Distinguishing Prodromal From First-Episode Psychosis Using Neuroanatomical Single-Subject Pattern Recognition. Schizophrenia Bulletin, 2013, 39, 1105-1114.	4.6	66
45	Estrogens and Gonadal Function in Schizophrenia and Related Psychoses. Current Topics in Behavioral Neurosciences, 2010, 8, 155-171.	0.0	64
46	Different duration of atâ€risk mental state associated with neurofunctional abnormalities. A multimodal imaging study. Human Brain Mapping, 2012, 33, 2281-2294.	3.7	64
47	Help-seeking and pathways to care in the early stages of psychosis. Social Psychiatry and Psychiatric Epidemiology, 2013, 48, 1033-1043.	3.4	63
48	What do we really know about late-onset schizophrenia?. European Archives of Psychiatry and Clinical Neuroscience, 1997, 247, 195-208.	3.4	62
49	New insights into the transposition mechanisms of IS6110 and its dynamic distribution between Mycobacterium tuberculosis Complex lineages. PLoS Genetics, 2018, 14, e1007282.	3.4	62
50	Development of Proteomic Prediction Models for Transition to Psychotic Disorder in the Clinical High-Risk State and Psychotic Experiences in Adolescence. JAMA Psychiatry, 2021, 78, 77.	11.4	62
51	Aberrant Current Source-Density and Lagged Phase Synchronization of Neural Oscillations as Markers for Emerging Psychosis. Schizophrenia Bulletin, 2015, 41, 919-929.	4.6	60
52	EEG microstates as biomarker for psychosis in ultra-high-risk patients. Translational Psychiatry, 2020, 10, 300.	4.9	59
53	Pituitary volume increase during emerging psychosis. Schizophrenia Research, 2011, 125, 41-48.	2.1	57
54	Disorganized Gyrification Network Properties During the Transition to Psychosis. JAMA Psychiatry, 2018, 75, 613.	11.4	57

#	ARTICLE	IF	CITATIONS
55	Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. International Journal of Neuropsychopharmacology, 2007, 10, S1-207.	2.1	56
56	Clinical trajectories in the ultra-high risk for psychosis population. Schizophrenia Research, 2018, 197, 550-556.	2.1	56
57	NEURAPROâ€ study protocol: a multicentre randomized controlled trial of omegaâ€3 fatty acids and cognitiveâ€behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Microbial Biotechnology, 2017, 11, 418-428.	1.9	55
58	Quantitative genetics of life-history and morphology in a rare plant, Senecio integrifolius. Heredity, 1993, 70, 503-514.	2.7	54
59	Dysregulated Lipid Metabolism Precedes Onset of Psychosis. Biological Psychiatry, 2021, 89, 288-297.	1.3	53
60	Hippocampal volume in subjects at high risk of psychosis: A longitudinal MRI study. Schizophrenia Research, 2012, 142, 217-222.	2.1	52
61	Inferior Frontal Cortex Modulation with an Acute Dose of Heroin During Cognitive Control. Neuropsychopharmacology, 2013, 38, 2231-2239.	5.6	52
62	Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial. Schizophrenia Research, 2019, 206, 67-74.	2.1	52
63	The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis. Biological Psychiatry, 2020, 87, 243-252.	1.3	52
64	Prediction of conversion to psychosis in individuals with an at-risk mental state. Current Opinion in Psychiatry, 2017, 30, 209-219.	6.6	50
65	Estrogens and SERMS as adjunctive treatments for schizophrenia. Frontiers in Neuroendocrinology, 2019, 53, 100743.	5.2	48
66	Modulation of motivational salience processing during the early stages of psychosis. Schizophrenia Research, 2015, 166, 17-23.	2.1	47
67	Fine motor function and neuropsychological deficits in individuals at risk for schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2006, 256, 201-206.	3.4	46
68	Alterations in the hippocampus and thalamus in individuals at high risk for psychosis. NPJ Schizophrenia, 2016, 2, 16033.	4.5	46
69	Prediction of psychosis using neural oscillations and machine learning in neuroleptic-naïve at-risk patients. World Journal of Biological Psychiatry, 2016, 17, 285-295.	2.7	43
70	EEG spectral power and negative symptoms in at-risk individuals predict transition to psychosis. Schizophrenia Research, 2010, 123, 208-216.	2.1	42
71	Abnormal effective connectivity and psychopathological symptoms in the psychosis high-risk state. Journal of Psychiatry and Neuroscience, 2014, 39, 239-248.	2.8	41
72	Structural Network Disorganization in Subjects at Clinical High Risk for Psychosis. Schizophrenia Bulletin, 2017, 43, sbw110.	4.6	40

#	ARTICLE	IF	CITATIONS
73	Sex differences in prolactin levels in emerging psychosis: Indication for enhanced stress reactivity in women. Schizophrenia Research, 2017, 189, 111-116.	2.1	40
74	Is age of onset in schizophrenia influenced by marital status?. Social Psychiatry and Psychiatric Epidemiology, 1992, 27, 122-128.	3.4	40
75	CuSCN as selective contact in solution-processed small-molecule organic solar cells leads to over 7% efficient porphyrin-based device. Journal of Materials Chemistry A, 2016, 4, 11009-11022.	10.5	39
76	Plasma and serum brain-derived neurotrophic factor (BDNF) levels and their association with neurocognition in at-risk mental state, first episode psychosis and chronic schizophrenia patients. World Journal of Biological Psychiatry, 2019, 20, 545-554.	2.7	39
77	Dysfunctional insular connectivity during reward prediction in patients with first-episode psychosis. Journal of Psychiatry and Neuroscience, 2016, 41, 367-376.	2.8	37
78	Acute effects of heroin on emotions in heroin–dependent patients. American Journal on Addictions, 2013, 22, 598-604.	1.9	36
79	Acute Effects of Intravenous Heroin on the Hypothalamic-Pituitary-Adrenal Axis Response. Journal of Clinical Psychopharmacology, 2013, 33, 193-198.	1.4	35
80	Anterior cingulate pathology in the prodromal stage of schizophrenia. NeuroImage, 2008, 39, 553-554.	4.4	34
81	Orbitofrontal response to drug-related stimuli after heroin administration. Addiction Biology, 2015, 20, 570-579.	2.7	34
82	Age-related brain structural alterations as an intermediate phenotype of psychosis. Journal of Psychiatry and Neuroscience, 2017, 42, 307-319.	2.8	34
83	Does menopausal transition really influence mental health? Findings from the prospective long–term <scp>Z</scp>urich study. World Psychiatry, 2016, 15, 146-154.	9.6	33
84	WFSBP and IAWMH Guidelines for the treatment of alcohol use disorders in pregnant women. World Journal of Biological Psychiatry, 2019, 20, 17-50.	2.7	32
85	Psychische Störungen und Erkrankungen nach der Entbindung. Fortschritte Der Neurologie Psychiatrie, 1997, 65, 97-107.	0.2	31
86	The Self-screen-Prodrome as a short screening tool for pre-psychotic states. Schizophrenia Research, 2010, 123, 217-224.	2.1	31
87	Duration of untreated psychosis and cognitive functioning. Schizophrenia Research, 2013, 145, 43-49.	2.1	31
88	Super proton/electron mixed conduction in graphene oxide hybrids by intercalating sulfate ions. Journal of Materials Chemistry A, 2015, 3, 20892-20895.	10.5	31
89	Individualized Prediction of Transition to Psychosis in 1,676 Individuals at Clinical High Risk: Development and Validation of a Multivariable Prediction Model Based on Individual Patient Data Meta-Analysis. Frontiers in Psychiatry, 2019, 10, 345.	2.7	30
90	Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people. Schizophrenia Research, 2020, 226, 44-51.	2.1	30

#	ARTICLE	IF	CITATIONS
91	Cost of attempted suicide: a retrospective study of extent and associated factors. Swiss Medical Weekly, 2012, 142, w13648.	1.5	29
92	Cannabis use and brain structural alterations of the cingulate cortex in early psychosis. Psychiatry Research - Neuroimaging, 2013, 214, 102-108.	1.9	28
93	Hyper-methylation of the upstream CpG island shore is a likely mechanism of GPER1 silencing in breast cancer cells. Gene, 2017, 614, 65-73.	2.3	28
94	Anatomical integrity within the inferior fronto-occipital fasciculus and semantic processing deficits in schizophrenia spectrum disorders. Schizophrenia Research, 2020, 218, 267-275.	2.1	28
95	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. Molecular Psychiatry, 2021, 26, 4529-4543.	8.2	28
96	EEG: a helpful tool in the prediction of psychosis. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 257-262.	3.4	27
97	Association of Frontal Gray Matter Volume and Cerebral Perfusion in Heroin Addiction: A Multimodal Neuroimaging Study. Frontiers in Psychiatry, 2013, 4, 135.	2.7	27
98	Individualized prediction of psychosis in subjects with an at-risk mental state. Schizophrenia Research, 2019, 214, 18-23.	2.1	27
99	Oestrogens and schizophrenia. Current Opinion in Psychiatry, 2003, 16, 187-192.	6.6	26
100	Clinical and functional ultra-long-term outcome of patients with a clinical high risk (CHR) for psychosis. European Psychiatry, 2019, 62, 30-37.	0.2	26
101	Duration of untreated psychosis/illness and brain volume changes in early psychosis. Psychiatry Research, 2017, 255, 332-337.	3.4	25
102	Association of Adverse Outcomes With Emotion Processing and Its Neural Substrate in Individuals at Clinical High Risk for Psychosis. JAMA Psychiatry, 2020, 77, 190.	11.4	25
103	The relationship between negative symptoms and cognitive functioning in patients at clinical high risk for psychosis. Psychiatry Research, 2018, 268, 21-27.	3.4	24
104	Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial. Frontiers in Psychiatry, 2019, 10, 393.	2.7	24
105	Gender differences in first selfâ€perceived signs and symptoms in patients with an atâ€risk mental state and firstâ€episode psychosis. Microbial Biotechnology, 2019, 13, 582-588.	1.9	24
106	Normalizing effect of heroin maintenance treatment on stress-induced brain connectivity. Brain, 2015, 138, 217-228.	8.0	23
107	Screening for Adult Attention-Deficit/Hyperactivity Disorder in a Psychiatric Outpatient Population with Specific Focus on Sex Differences. Frontiers in Psychiatry, 2017, 8, 115.	2.7	23
108	Early detection of psychosis: helpful or stigmatizing experience? A qualitative study. Microbial Biotechnology, 2018, 12, 66-73.	1.9	23

#	ARTICLE	IF	CITATIONS
109	An overlapping pattern of cerebral cortical thinning is associated with both positive symptoms and aggression in schizophrenia via the ENIGMA consortium. Psychological Medicine, 2020, 50, 2034-2045.	5.2	23
110	Negative symptoms in neuroleptic-naïve patients with first-episode psychosis correlate with QEEG parameters. Schizophrenia Research, 2009, 115, 231-236.	2.1	22
111	Estrogens and Schizophrenia. , 2005, , 31-52.		21
112	Classifying individuals at high-risk for psychosis based on functional brain activity during working memory processing. NeuroImage: Clinical, 2015, 9, 555-563.	2.8	21
113	Orbitofrontal-Striatal Structural Alterations Linked to Negative Symptoms at Different Stages of the Schizophrenia Spectrum. Schizophrenia Bulletin, 2021, 47, 849-863.	4.6	21
114	Cingulate Volume Abnormalities in Emerging Psychosis. Current Pharmaceutical Design, 2012, 18, 495-504.	1.9	21
115	Schizophrenic symptomatology varies with serum estradiol levels during menstrual cycle. Schizophrenia Research, 1992, 6, 114-115.	2.1	20
116	Veblen on the machine process and technological change. Cambridge Journal of Economics, 2010, 34, 601-615.	1.4	20
117	Evidence for an agitated–aggressive syndrome predating the onset of psychosis. Schizophrenia Research, 2014, 157, 26-32.	2.1	20
118	Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning – Results from the EU-GEI study. European Psychiatry, 2019, 59, 52-59.	0.2	20
119	Pan-azole-Resistant Candida guilliermondii from a Leukemia Patient's Silent Funguria. Mycopathologia, 2010, 169, 457-459.	3.0	19
120	Relation between self-perceived stress, psychopathological symptoms and the stress hormone prolactin in emerging psychosis. Journal of Psychiatric Research, 2021, 136, 428-434.	3.2	19
121	Neurobiologically Based Stratification of Recent-Onset Depression and Psychosis: Identification of Two Distinct Transdiagnostic Phenotypes. Biological Psychiatry, 2022, 92, 552-562.	1.3	19
122	Die Zwangseinweisung psychiatrischer Patienten im nationalen und internationalen Vergleich - Häufigkeiten und Einflußfaktoren. Fortschritte Der Neurologie Psychiatrie, 1992, 60, 375-382.	0.2	18
123	The gene family coding for the light-harvesting polypeptides of Photosystem I of the red alga Galdieria sulphuraria. Photosynthesis Research, 2001, 68, 121-130.	2.9	18
124	Quantum dynamics simulation of intramolecular singlet fission in covalently linked tetracene dimer. Journal of Chemical Physics, 2021, 155, 194101.	3.1	18
125	Are neurological soft signs pre-existing markers in individuals with an at-risk mental state for psychosis?. Psychiatry Research, 2013, 210, 427-431.	3.4	17
126	Can cognitive deficits facilitate differential diagnosis between at–risk mental state for psychosis and depressive disorders?. Microbial Biotechnology, 2013, 7, 381-390.	1.9	17

#	Article	IF	Citations
127	Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis. Molecular Psychiatry, 2021, 26, 2590-2604.	8.2	17
128	Altered prefrontal connectivity after acute heroin administration during cognitive control. International Journal of Neuropsychopharmacology, 2014, 17, 1375-1385.	2.1	16
129	Increased superior frontal gyrus activation during working memory processing in psychosis: Significant relation to cumulative antipsychotic medication and to negative symptoms. Schizophrenia Research, 2016, 175, 20-26.	2.1	16
130	Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial. Behaviour Research and Therapy, 2020, 124, 103527.	3.3	16
131	EEG Microstate Differences in Medicated vs. Medication-Naïve First-Episode Psychosis Patients. Frontiers in Psychiatry, 2020, 11, 600606.	2.7	16
132	Emotion Recognition and Adverse Childhood Experiences in Individuals at Clinical High Risk of Psychosis. Schizophrenia Bulletin, 2020, 46, 823-833.	4.6	16
133	Elternschaft und Belastungserleben: Psychometrische Überprüfung des Parenting-Stress-Index (PSI) an einer deutschsprachigen Stichprobe. PPmP Psychotherapie Psychosomatik Medizinische Psychologie, 2009, 59, 224-233.	0.4	15
134	Single- and multiple-dose pharmacokinetics of arginase inhibitor Nω-hydroxy-nor-L-arginine, and its effect on plasma amino acids concentrations in Wistar rats. General Physiology and Biophysics, 2014, 33, 189-198.	0.9	15
135	Altered Insular Function during Aberrant Salience Processing in Relation to the Severity of Psychotic Symptoms. Frontiers in Psychiatry, 2016, 7, 189.	2.7	15
136	Sex differences in cognitive functioning of patients at-risk for psychosis and healthy controls: Results from the European Gene–Environment Interactions study. European Psychiatry, 2020, 63, e25.	0.2	15
137	Late-Onset Schizophrenia Versus Paranoid Psychoses: A Valid Diagnostic Distinction?. American Journal of Geriatric Psychiatry, 2003, 11, 595-604.	1.1	15
138	Superior temporal gray and white matter changes in schizophrenia or antipsychotic related effects?. Schizophrenia Research, 2009, 113, 109-110.	2.1	14
139	Relationship between jumping to conclusions and clinical outcomes in people at clinical high-risk for psychosis. Psychological Medicine, 2022, 52, 1569-1577.	5.2	14
140	Psychische Erkrankungen bei Frauen - einige Argumente für eine geschlechtersensible Psychiatrie und Psychotherapie/ Mental diseases in women - some arguments for a gender-sensitive psychiatry and psychotherapy. Zeitschrift Fur Psychosomatische Medizin Und Psychotherapie, 2000, 46, 129-139.	0.9	13
141	Werden psychisch Kranke zu schnell in die Rente 'abgeschoben'?. Psychiatrische Praxis, 2005, 32, 172-176.	0.5	13
142	Neuroimaging and Resilience Factors - Staging of the At-risk Mental State?. Current Pharmaceutical Design, 2012, 18, 416-421.	1.9	13
143	Hippocampal volume correlates with attenuated negative psychotic symptoms irrespective of antidepressant medication. NeuroImage: Clinical, 2015, 8, 230-237.	2.8	13
144	Correlations between self–rating and observer–rating of psychopathology in at–risk mental state and first–episode psychosis patients: influence of disease stage and gender. Microbial Biotechnology, 2017, 11, 461-470.	1.9	13

#	ARTICLE	IF	CITATIONS
145	Development and Validation of a Dynamic Risk Prediction Model to Forecast Psychosis Onset in Patients at Clinical High Risk. Schizophrenia Bulletin, 2019, 46, 252-260.	4.6	13
146	Predictors of study drop-out and service disengagement in patients at clinical high risk for psychosis. Social Psychiatry and Psychiatric Epidemiology, 2020, 55, 539-548.	3.4	13
147	Prediction of clinical outcomes beyond psychosis in the <scp>ultra‐high</scp> risk for psychosis population. Microbial Biotechnology, 2021, 15, 642-651.	1.9	13
148	Impact of Comorbid Affective Disorders on Longitudinal Clinical Outcomes in Individuals at Ultra-high Risk for Psychosis. Schizophrenia Bulletin, 2022, 48, 100-110.	4.6	13
149	Neural oscillations in antipsychotic-naïve patients with a first psychotic episode. World Journal of Biological Psychiatry, 2016, 17, 296-307.	2.7	12
150	Sexually dimorphic subcortical brain volumes in emerging psychosis. Schizophrenia Research, 2018, 199, 257-265.	2.1	12
151	High-transmission hybrid-effect-assisted nanoaperture. Optics Letters, 2006, 31, 655.	3.3	11
152	Survey of the European Psychiatric Association on the European status and perspectives in early detection and intervention in at‐risk mental state and first‐episode psychosis. Microbial Biotechnology, 2019, 13, 853-858.	1.9	11
153	Association of antidepressants with brain morphology in early stages of psychosis: an imaging genomics approach. Scientific Reports, 2019, 9, 8516.	3.4	11
154	Obsessive-Compulsive Symptoms and Other Symptoms of the At-risk Mental State for Psychosis: A Network Perspective. Schizophrenia Bulletin, 2021, 47, 1018-1028.	4.6	11
155	Verbal memory performance predicts remission and functional outcome in people at clinical high-risk for psychosis. Schizophrenia Research: Cognition, 2022, 28, 100222.	1.3	11
156	Pituitary gland volume in at-risk mental state for psychosis: a longitudinal MRI analysis. CNS Spectrums, 2015, 20, 122-129.	1.3	10
157	Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis. Schizophrenia Research, 2020, 226, 52-60.	2.1	10
158	Omega‐3 fatty acids and neurocognitive ability in young people at ultra‐high risk for psychosis. Microbial Biotechnology, 2021, 15, 874-881.	1.9	10
159	Wilhelm Griesinger and the Concept of Community Care in 19th-Century Germany. Psychiatric Services, 1994, 45, 818-822.	2.2	9
160	50 Jahre nach Manfred Bleuler. Der Nervenarzt, 1997, 68, 159-170.	0.8	9
161	Can neuropsychological testing facilitate differential diagnosis between at-risk mental state (ARMS) for psychosis and adult attention-deficit/hyperactivity disorder (ADHD)?. European Psychiatry, 2018, 52, 38-44.	0.2	9
162	Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial. Schizophrenia Research, 2020, 218, 48-54.	2.1	9

#	Article	IF	Citations
163	Multimodal prognosis of negative symptom severity in individuals at increased risk of developing psychosis. Translational Psychiatry, 2021, 11, 312.	4.9	9
164	Clinical, Brain, and Multilevel Clustering in Early Psychosis and Affective Stages. JAMA Psychiatry, 2022, 79, 677.	11.4	9
165	Changing patterns of mental health care in Germany. International Journal of Law and Psychiatry, 1996, 19, 391-411.	0.9	8
166	Cavum septum pellucidum in patients with first episode psychosis and individuals at high risk of psychosis. European Psychiatry, 2007, 22, 264-264.	0.2	8
167	Education and Reproductive Autonomy: The Case of Married Nigerian Women. Narrative Inquiry in Bioethics, 2017, 7, 231-244.	0.1	8
168	The neuropsychology of emerging psychosis and the role of working memory in episodic memory encoding. Psychology Research and Behavior Management, 2018, Volume 11, 157-168.	2.9	8
169	Wirken Ö—strogene antipsychotisch?. Fortschritte Der Neurologie Psychiatrie, 1994, 62, 22-28.	0.2	7
170	High time for a paradigm shift in psychiatry. World Psychiatry, 2016, 15, 131-133.	9.6	7
171	The Frankfurt Complaint Questionnaire for self‐assessment of basic symptoms in the early detection of psychosis—Factor structure, reliability, and predictive validity. International Journal of Methods in Psychiatric Research, 2018, 27, e1600.	2.3	7
172	Exploring the predictive power of the unspecific risk category of the Basel Screening Instrument for Psychosis. Microbial Biotechnology, 2019, 13, 969-976.	1.9	7
173	Implementation of early detection and intervention services for psychosis in Central and Eastern Europe: Current status. Microbial Biotechnology, 2019, 13, 1283-1288.	1.9	7
174	The Augmented Classical Twin Design: Incorporating Genome‐Wide Identity by Descent Sharing Into Twin Studies in Order to Model Violations of the Equal Environments Assumption. Behavior Genetics, 2021, 51, 223-236.	2.0	7
175	Characterization and prediction of clinical pathways of vulnerability to psychosis through graph signal processing. ELife, 2021, 10, .	5.9	7
176	Perinatal mental health service provision in Switzerland and in the UK. Swiss Medical Weekly, 2015, 145, w14011.	1.5	7
177	Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis. Translational Psychiatry, 2022, 12, .	4.9	7
178	Symptom Overlap and Screening for Symptoms of Attention-Deficit/Hyperactivity Disorder and Psychosis Risk in Help-Seeking Psychiatric Patients. Frontiers in Psychiatry, 2017, 8, 206.	2.7	6
179	Bride price payment and women's autonomy: Findings from qualitative interviews from Nigeria. Women and Health, 2019, 59, 775-788.	1.1	6
180	Pre-training inter-rater reliability of clinical instruments in an international psychosis research project. Schizophrenia Research, 2021, 230, 104-107.	2.1	6

#	Article	IF	Citations
181	Association between tobacco use and symptomatology in individuals at ultra-high risk to develop a psychosis: A longitudinal study. Schizophrenia Research, 2021, 236, 48-53.	2.1	6
182	Weibliche Rollen und psychische Gesundheit. , 2016, , 19-34.		6
183	Are all quantum measurements reducible to local position measurements?. Journal of Physics A, 1991, 24, L425-L430.	1.6	5
184	Theory of natural circular dichroism in x-ray Raman scattering from molecules. Physical Review A, 1997, 55, 2716-2722.	2.5	5
185	Late-Onset Schizophrenia Versus Paranoid Psychoses. American Journal of Geriatric Psychiatry, 2003, 11, 595-604.	1.1	5
186	Symptom control, functioning and satisfaction among Swiss patients treated with risperidone long-acting injectable. International Journal of Psychiatry in Clinical Practice, 2006, 10, 174-181.	2.7	5
187	The attenuated psychosis syndrome in DSM-5. Schizophrenia Research, 2013, 151, 295.	2.1	5
188	Pourquoi et comment soigner plus précocement les troubles psychotiques?. Presse Medicale, 2016, 45, 992-1000.	2.1	5
189	T49. THE NEURAPRO STUDY: ADHERENCE TO STUDY MEDICATION. Schizophrenia Bulletin, 2018, 44, S132-S133.	4.6	5
190	Effect of cantilevers' dimensions on phase contrast in multifrequency atomic force microscopy. Microscopy Research and Technique, 2019, 82, 1438-1447.	2.3	5
191	Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?. Biological Psychiatry, 2019, 85, e35-e39.	1.3	5
192	The association between migrant status and transition in an ultra-high risk for psychosis population. Social Psychiatry and Psychiatric Epidemiology, 2021, 56, 943-952.	3.4	5
193	Menopause and Mental Health. Mental Health and Illness Worldwide, 2020, , 147-173.	0.0	5
194	Patient-Identified Priorities Leading to Attempted Suicide. Crisis, 2018, 39, 37-46.	1.5	5
195	Therapist-client sex in psychotherapy: attitudes of professionals and students towards ethical arguments. Swiss Medical Weekly, 2015, 145, w14099.	1.5	5
196	Basic Symptoms Are Associated With Age in Patients With a Clinical High-Risk State for Psychosis: Results From the PRONIA Study. Frontiers in Psychiatry, 2020, 11, 552175.	2.7	5
197	Machine learning based prediction and the influence of complement â€" Coagulation pathway proteins on clinical outcome: Results from the NEURAPRO trial. Brain, Behavior, and Immunity, 2022, 103, 50-60.	6.3	5
198	Insular pathology in the at-risk mental state. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 254-255.	3.4	4

#	ARTICLE	IF	CITATIONS
199	The role of vulnerability factors in individuals with an at-risk mental state of psychosis. Neuropsychiatrie, 2016, 30, 18-26.	2.1	4
200	Outcome of individuals â€œnot at risk of psychosisâ€•and prognostic accuracy of the Basel Screening Instrument for Psychosis (BSIP). Microbial Biotechnology, 2018, 12, 907-914.	1.9	4
201	From Speech Illusions to Onset of Psychotic Disorder: Applying Network Analysis to an Experimental Measure of Aberrant Experiences. Schizophrenia Bulletin Open, 2020, 1, .	1.7	4
202	Machine Learning for Large-Scale Quality Control of 3D Shape Models in Neuroimaging. Lecture Notes in Computer Science, 2017, 10541, 371-378.	1.0	4
203	FrÃ¼herkennung schizophrener Psychosen bei MÃ¤nnern und Frauen. Therapeutische Umschau Revue Therapeutique, 2007, 64, 337-343.	0.1	4
204	Depression in der Schwangerschaft. Therapeutische Umschau Revue Therapeutique, 2010, 67, 571-575.	0.1	4
205	The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trial. Brain, Behavior, and Immunity, 2022, 99, 147-156.	6.3	4
206	Twelve-Month Cognitive Trajectories in Individuals at Ultra-High Risk for Psychosis: A Latent Class Analysis. Schizophrenia Bulletin Open, 2022, 3, .	1.7	4
207	Latent state-trait structure of BPRS subscales in clinical high-risk state and first episode psychosis. Scientific Reports, 2022, 12, 6652.	3.4	4
208	Influence of cannabis use on incidence of psychosis in people at clinical high risk. Psychiatry and Clinical Neurosciences, 2023, 77, 469-477.	2.3	4
209	First selfâ€perceived signs and symptoms in emerging psychosis compared with depression. Microbial Biotechnology, 2012, 6, 455-459.	1.9	3
210	Der Einfluss eines elektronischen Erinnerungssystems auf die leitlinientreue Behandlung von psychotischen Erkrankungen. Neuropsychiatrie, 2016, 30, 191-197.	2.1	3
211	Evaluating verbal learning and memory in patients with an at-risk mental state or first episode psychosis using structural equation modelling. PLoS ONE, 2018, 13, e0196936.	2.5	3
212	No associations between medial temporal lobe volumes and verbal learning/memory in emerging psychosis. European Journal of Neuroscience, 2019, 50, 3060-3071.	3.5	3
213	Editorial: Sex and the Suffering Brain - A Call for Sex-Stratified Analyses in Psychiatric Research. Frontiers in Psychiatry, 2022, 13, 849009.	2.7	3
214	Ã–strogene und Schizophrenie - Patientinnen an der Schnittstelle zwischen Psychiatrie und GynÃ¤kologie. Geburtshilfe Und Frauenheilkunde, 2002, 62, 429-435.	0.4	2
215	Neural effects of heroin â€" Relation to anxiety stress. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 816-817.	5.0	2
216	T9. CROSS-SECTIONAL ASSOCIATION OF MEMBRANE FATTY ACID COMPOSITION AND PSYCHOPATHOLOGY IN THE NEURAPRO-E STUDY. Schizophrenia Bulletin, 2018, 44, S116-S116.	4.6	2

#	Article	IF	Citations
217	Novel Gyrification Networks Reveal Links with Psychiatric Risk Factors in Early Illness. Cerebral Cortex, 2022, 32, 1625-1636.	3.2	2
218	The relationship between grey matter volume and clinical and functional outcomes in people at clinical high risk for psychosis. Schizophrenia Bulletin Open, 0, , .	1.7	2
219	The role of gender as a barrier to the professional development of psychiatrists. European Psychiatry, 2023, 66, .	0.2	2
220	Role of fO2 on fluid saturation in oceanic basalt (reply). Nature, 2004, 430, 1-2.	36.2	1
221	Alpha oscillations underlie working memory abnormalities in the psychosis high-risk state. Biological Psychology, 2017, 126, 12-18.	2.3	1
222	Abnormal brain connectivity during error-monitoring in the psychosis high-risk state. Schizophrenia Research, 2018, 193, 261-262.	2.1	1
223	F25. NEURAPRO REVISITED: INCREASES IN LONG-CHAIN OMEGA-3 FATTY ACIDS IMPROVE FUNCTIONAL AND SYMPTOMATIC OUTCOMES IN ULTRAHIGH RISK PATIENTS. Schizophrenia Bulletin, 2018, 44, S228-S228.	4.6	1
224	S136. A NOVEL APPROACH FOR DEVELOPING PREDICTION MODEL OF TRANSITION TO PSYCHOSIS: DYNAMIC PREDICTION USING JOINT MODELLING. Schizophrenia Bulletin, 2018, 44, S378-S379.	4.6	1
225	Voxel-Based Morphometry Correlates of an Agitated-Aggressive Syndrome in the At-Risk Mental State for Psychosis and First Episode Psychosis. Scientific Reports, 2018, 8, 16516.	3.4	1
226	O8.8. NEUROCOGNITION IN ULTRA-HIGHRISK INDIVIDUALS AND RELATIONSHIP TO TRANSITION TO PSYCHOSIS, DEPRESSIVE DISORDER, AND FUNCTIONING: FINDINGS FROM THE NEURAPRO TRIAL. Schizophrenia Bulletin, 2018, 44, S99-S99.	4.6	1
227	Vulnerability and Protective Factors for Mental Health: A Rereading in Gender Perspective. , 2019, , 25-36.		1
228	Increased Symptom Consolidation Preceding Transition to Psychosis: A Phenomenological Network Study. SSRN Electronic Journal, 0, , .	0.3	1
229	Professional Conduct and Handling Misconduct in Psychotherapy: Ethical Practice between Boundaries, Relationships, and Reality. , 0, , 1001-1018.		1
230	Editorial: Women and the Pandemic. Archives of Women's Mental Health, 2022, 25, 255.	2.8	1
231	Impact of adverse childhood experiences on educational achievements in young people at clinical high risk of developing psychosis. European Psychiatry, 2023, 66, .	0.2	1
232	Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk: A Multi-cohort Model Development Study. Schizophrenia Bulletin, 2024, 50, 579-588.	4.6	1
233	Pau Hana: Plantation Life and Labor in Hawaii. By Ronald Takaki. Honolulu: University of Hawaii Press, 1983. Pp. xiv, 213. $15.00.. Journal of Economic History, 1984, 44, 891-892.	1.4	0
234	Depression und Psychose in der Menopause - kann eine Hormontherapie hilfreich sein?. Psychiatrie Und Psychotherapie, 2011, 7, 129-134.	0.1	0

#	Article	IF	Citations
235	Sollen junge Menschen mit Psychoserisikosyndrom behandelt werden?. Neuropsychiatrie, 2013, 27, 153-156.	2.1	0
236	Depression in der Peripartalzeit â€" Diagnostik, Therapie und Prophylaxe. PSYCH Up2date, 2015, 9, 149-160.	0.2	0
237	Depression in der Peripartalzeit â€" Diagnostik, Therapie und Prophylaxe. Frauenheilkunde Up2date, 2017, 10, 531-545.	0.0	0
238	T212. THE INTRINSIC ORGANIZATION OF SYMPTOMS MARKS TRANSITION FROM HIGH-RISK STATE TO EARLY PSYCHOSIS: A PHENOMENOLOGICAL CONNECTIVITY STUDY. Schizophrenia Bulletin, 2018, 44, S199-S199.	4.6	0
239	O6.5. INVESTIGATING VARIABLES FROM THE NAPLS RISK CALCULATOR FOR PSYCHOSIS IN THE EU-GEI HIGH RISK STUDY. Schizophrenia Bulletin, 2019, 45, S177-S178.	4.6	0
240	T21. DEVELOPMENT OF PROTEOMIC PREDICTION MODELS FOR OUTCOMES IN THE CLINICAL HIGH RISK STATE AND PSYCHOTIC EXPERIENCES IN ADOLESCENCE: MACHINE LEARNING ANALYSES IN TWO NESTED CASE-CONTROL STUDIES. Schizophrenia Bulletin, 2020, 46, S238-S239.	4.6	0
241	T34. THE IMPACT OF ANTIDEPRESSANT USE ON THE TRANSITION TO PSYCHOSIS RATE IN THE NEURAPRO TRIAL. Schizophrenia Bulletin, 2020, 46, S244-S245.	4.6	0
242	S175. CLINICAL OUTCOMES IN PEOPLE AT HIGH RISK FOR PSYCHOSIS RELATED TO INTERACTIONS BETWEEN POLYGENIC RISK SCORES AND CHILDHOOD ADVERSITY. Schizophrenia Bulletin, 2020, 46, S104-S104.	4.6	0
243	Depression in der frühen Mutterschaft. Therapeutische Umschau Revue Therapeutique, 2010, 67, 576-580.	0.1	0
244	Traditional Methodology and Outcome Assessment in Studies on the Course of Schizophrenia. , 1999, , 249-258.		0
245	Früherkennung und Frühintervention bei beginnenden Psychosen. Neurotransmitter, 2015, 26, 50-54.	0.0	0
246	Appropriateness of Care and Joint Decision-Making Strategies. , 2016, , 207-209.		0
247	Menopause and Mental Health. Mental Health and Illness Worldwide, 2019, , 1-27.	0.0	0
248	The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youth at Ultra-High Risk for Psychosis. SSRN Electronic Journal, 0, , .	0.3	0
249	Probing the communication patterns of different chondrocyte subtypes in osteoarthritis at the single cell level using pattern recognition and manifold learning. Scientific Reports, 2023, 13, .	3.4	0
250	Do Cognitive Subtypes Exist in People at Clinical High Risk for Psychosis? Results From the EU-GEI Study. Schizophrenia Bulletin, 0, , .	4.6	0